Relevant to our results, previous studies have demonstrated that TLR4-mediated immune response to dying tumor cells is essential for the efficacy of anticancer chemotherapy and radiotherapy; specifically, it has been reported that in the treatment of established tumors with chemotherapy or radiotherapy the presence of TLR4 dictates the therapeutic outcome [51]. This evidence concerns the gene TLR4 and neoplasm.